- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 750KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 112KB)
Ravulizumab – July 2023
Ravulizumab (PNH): Solution concentrate for I.V. infusion 300 mg in 3 mL, Solution concentrate for I.V. infusion 1,100 mg in 11 mL; Ultomiris®
Last updated
27 October 2023